异体颜面复合组织移植患者术后糖尿病个体化降糖治疗一例  

Blood glucose control in a patient with diabetes mellitus after facial composite allotransplantation

作　　者：赖敬波[1] 王莉[1] 付建芳[1] 张南雁[1] 李德强[1] 郭树忠[2] 曹宏伟[1] 刘向阳[1] 姬秋和[1] 

机构地区：[1]解放军第四军医大学西京医院内分泌代谢科,西安710032 [2]解放军第四军医大学西京医院 整形外科,西安710032

出　　处：《中华全科医师杂志》2011年第5期341-343,共3页Chinese Journal of General Practitioners

摘　　要：对国内首例颜面部复合组织异体移植术及行不同免疫抑制剂和糖皮质激素治疗后出现血糖升高（14．3～33．3mmol／L）患者，在术后不同时期分别采用中效胰岛素（中性精蛋白胰岛素）10U、每日2次皮下注射方案治疗，空腹血糖为3．6～9．4mmol／L；持续皮下输注胰岛素方案，门冬胰岛素用量为21～96U／d，窄腹血糖为3．9—4．6mmol／L；口服降糖药物加每晚基础胰岛素10U补充治疗方案，空腹血糖为4．2～5．5mmol／L；口服二甲双胍、瑞格列奈治疗方案，空腹血糖为4．3—5．9mmol／L。血糖得到良好控制，避免了高血糖引发的各种急、慢性并发症。A facial allotransplanted patient presented hyperglycemia with blood glucose ranged 14. 3 - 33.3 mmol/L after receiving immunosuppressive drugs and glucocorlicoids. To control the blood glucose level, the patient was treated with two subcutaneous doses of 10 U human neutral protamine hagedorn （NPH） insulin, and the fasting glucose level came down to 3.6 - 9.4 mmol/L Then the continuous subcutaneous infusion of insulin aspart （ Novo Industri ） was administrated （ from 96 to 21 U/d ）, and the fasting blood glucose levels were 3. 9 -4. 6 mmol/L With oral administration of Mefformin and Repaglinide, the fasting blood glucose was maintained to 4. 3 -5. 9 mmol/L. With these medications, the blood glucose level of the patient was under good control and the acute and chronic complications of hyperglycemia were effectively prevented.

关 键 词：糖尿病 治疗 

分 类 号：R587.1[医药卫生—内分泌]